Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders
Under the terms of the agreement,
“Our CodeEvolver® platform technology enables the rapid engineering of novel genetic sequences that encode more efficacious proteins. The prospects of these improved sequences for the development of differentiated gene therapies for patients with rare diseases therefore holds great promise,” stated
Gjalt Huisman, Codexis’ Senior Vice-President, and General Manager, Novel Biotherapeutics added, “We are looking forward to working with
Terms of Agreement
Under the terms of the agreement, the parties will begin collaborative work on three initial programs.
To the extent that statements contained in this press release are not descriptions of historical facts regarding
LHA Investor Relations
Source: Codexis, Inc.